Clinical Trial Update: Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating caplacizumab in combination with immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• CABLIVI (CAPLACIZUMAB)

Snippet

Sponsor: Sanofi | Conditions: Thrombotic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2025-12-30